{"gene":"HNRNPH2","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2016,"finding":"De novo missense variants in HNRNPH2 located within the nuclear localization signal (NLS) cause a neurodevelopmental disorder in females, establishing that HNRNPH2 is an X-linked RNA-binding protein critical for neurodevelopment; the NLS variants were predicted to disrupt nuclear import of the protein.","method":"Whole-exome sequencing of six independent families with a shared neurodevelopmental phenotype; bioinformatic prediction of variant deleteriousness","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 — genetic identification of disease-causing NLS variants; single study, no in vitro functional rescue","pmids":["27545675"],"is_preprint":false},{"year":2020,"finding":"Chicken hnRNPH2 physically interacts with the N-terminal CARD-containing domain of chicken MDA5 (chMDA5-N) and impairs the interaction between chMDA5-N and the downstream adaptor MAVS, thereby suppressing chMDA5-mediated type I interferon (IFN-β) production.","method":"Pulldown assay with mass spectrometry to identify chMDA5-N interactors; cloning and overexpression of 64 candidate genes; co-immunoprecipitation confirming hnRNPH2–chMDA5-N association; reporter assay measuring IFN-β production upon hnRNPH2 expression","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 3 — pulldown/Co-IP plus functional reporter assay; single lab, single study, chicken ortholog","pmids":["33123126"],"is_preprint":false},{"year":2021,"finding":"Pathogenic HNRNPH2 missense variants p.(Arg206Gln) and p.(Pro209Leu), located within the NLS, cause dysfunctional nucleocytoplasmic shuttling (aberrant cytoplasmic accumulation), whereas the p.(Arg114Trp) variant within the second quasi-RNA-recognition motif (qRRM) shows reduced interaction with members of the large assembly of splicing regulators (LASR) complex and causes substantial alterations in alternative splicing and global transcriptome changes in patient fibroblasts.","method":"Functional in vitro characterization of three HNRNPH2 missense variants: subcellular localization assays for NLS variants; co-immunoprecipitation for LASR interaction of Arg114Trp variant; RNA-sequencing of primary patient fibroblasts","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (localization assay, Co-IP, RNA-seq) in a single study with patient-derived cells","pmids":["34907471"],"is_preprint":false},{"year":2020,"finding":"The GLA and HNRNPH2 genes are divergently paired on the X chromosome and their expression is co-regulated by a shared bidirectional promoter (BDP) that lacks TATA boxes, contains CpG islands, and harbors binding sites for YY1 and NRF1 transcription factors; nuclear run-on assays confirmed active transcription from this BDP in 293T cells.","method":"Bioinformatics analysis of locus architecture; nuclear run-on transcription assay; chromatin immunoprecipitation (ChIP) for TF binding; methylation-specific PCR across cell lines","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 2 — nuclear run-on and ChIP provide direct experimental evidence of BDP activity; single lab study","pmids":["33456521"],"is_preprint":false},{"year":2023,"finding":"HNRNPH2 NLS mutations (human-equivalent knockin) reduce interaction with the nuclear transport receptor Kapβ2 (Transportin-1) and cause modest cytoplasmic accumulation of hnRNPH2 in vivo; knockin mice recapitulate the human disorder (impaired motor/cognitive functions, audiogenic seizures, reduced male survival), whereas HNRNPH2-KO mice show no phenotype because they upregulate the paralog Hnrnph1, a compensation that fails in knockin mice, indicating the disorder involves toxic gain-of-function or complex loss-of-function with impaired paralog compensation.","method":"Knockin and knockout mouse models with human-equivalent mutations; behavioral testing (motor, cognitive); audiogenic seizure assay; subcellular fractionation/immunofluorescence for localization; co-immunoprecipitation for Kapβ2 interaction; Western blotting for Hnrnph1 upregulation","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 — multiple knockin and KO lines, orthogonal methods (Co-IP, localization, behavioral phenotyping), mechanistic rescue by paralog upregulation","pmids":["37463454"],"is_preprint":false},{"year":2023,"finding":"A crystal/structural study of Karyopherin-β2 (Transportin-1) bound to HNRNPH2 residues 204–215 revealed a proline-tyrosine NLS (PY-NLS) containing the motif 206RPGPY210 followed by a novel binding epitope 211DRP213 that contacts Karyopherin-β2 W373; mutations at each site decrease Karyopherin-β2 binding affinity 70–100 fold, explaining cytoplasmic accumulation of disease-associated HNRNPH2 variants; this epitope is shared with close paralogs HNRNPH1 and HNRNPF.","method":"Crystal structure of Karyopherin-β2•HNRNPH2 complex; site-directed mutagenesis of NLS residues; binding affinity measurements","journal":"bioRxiv (preprint)","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis and quantitative binding measurements in a single study","pmids":["36711837"],"is_preprint":true},{"year":2025,"finding":"ASO-mediated knockdown of Hnrnph2 in mutant knockin mice rescues audiogenic seizures, motor deficits, and cognitive phenotypes and induces compensatory upregulation of Hnrnph1; mechanistically, HNRNPH2 regulates alternative splicing of HNRNPH1 pre-mRNA to control HNRNPH1 protein levels, establishing an autoregulatory splicing relationship between the two paralogs.","method":"Intracerebroventricular ASO injection in neonatal and juvenile knockin mice; behavioral and electrophysiological phenotype rescue assays; Western blotting and RT-PCR for Hnrnph1 upregulation; alternative splicing analysis of HNRNPH1 by RNA-seq in human iPSC-derived neurons treated with HNRNPH2 ASO","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo rescue with multiple phenotypic readouts plus mechanistic splicing analysis in iPSC-derived neurons; peer-reviewed","pmids":["42018666"],"is_preprint":false},{"year":2025,"finding":"A de novo HNRNPH2 variant p.(Pro213Leu) disrupts the interaction between hnRNPH2 and its target transcripts, leading to downregulation of myelination-related genes, impaired oligodendrocyte progenitor cell differentiation, and myelination defects in knockin mice; the myelin-enhancing drug benztropine rescues myelination, myelin gene expression, and cognitive deficits in these mice.","method":"Hnrnph2P213L knockin mouse model; RNA immunoprecipitation or binding assays to assess target transcript interaction; immunohistochemistry/myelin staining; gene expression analysis of myelin-related genes; benztropine pharmacological rescue with behavioral testing","journal":"Journal of genetics and genomics","confidence":"High","confidence_rationale":"Tier 2 — knockin model with defined molecular mechanism (disrupted RNA binding), cellular phenotype (OPC differentiation), and pharmacological rescue","pmids":["41443536"],"is_preprint":false},{"year":2026,"finding":"RNA G-quadruplexes (rG4s) mediate cooperative binding of HNRNPH to RNA: rG4 unfolding by HNRNPH exposes multiple G-rich binding sites, establishing indirect cooperativity that is amplified to produce switch-like splicing regulation of hundreds of exons; this mechanism is relevant in breast cancer where rG4-disrupting variants alter HNRNPH-dependent splicing patterns.","method":"High-throughput in vivo and in vitro binding studies; theoretical modeling of cooperativity; rG4 unfolding/structure assays; splicing reporter assays; analysis of breast cancer patient data for rG4-disrupting variants","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vitro and in vivo methods plus modeling; preprint, not yet peer-reviewed; the paper uses 'HNRNPH' generically but is consistent with H1/H2 family","pmids":["41867855"],"is_preprint":true}],"current_model":"HNRNPH2 is a nuclear RNA-binding protein imported via a PY-NLS recognized by Karyopherin-β2/Transportin-1 (residues 204–215 including 206RPGPY210 and a novel 211DRP213 epitope); disease-causing NLS mutations reduce Kapβ2 binding 70–100-fold and cause cytoplasmic accumulation, while qRRM mutations reduce interaction with the LASR splicing complex and broadly disrupt alternative splicing; HNRNPH2 also autoregulates its paralog HNRNPH1 through alternative splicing control, engages RNA G-quadruplexes to achieve cooperative switch-like splicing regulation, and in oligodendrocytes its target-transcript binding is required for myelination-related gene expression and OPC differentiation."},"narrative":{"teleology":[{"year":2016,"claim":"Identification of de novo HNRNPH2 NLS variants in unrelated females established that this X-linked RNA-binding protein is essential for neurodevelopment, raising the mechanistic question of how NLS disruption causes disease.","evidence":"Whole-exome sequencing of six independent families with neurodevelopmental phenotypes; bioinformatic prediction of variant effects","pmids":["27545675"],"confidence":"Medium","gaps":["No functional validation of NLS variants at the protein level","Disease mechanism (loss-of-function vs. gain-of-function) was unknown","Specific splicing targets in the nervous system were uncharacterized"]},{"year":2021,"claim":"Functional characterization of patient-derived variants revealed that NLS mutations cause cytoplasmic mislocalization whereas a qRRM2 mutation disrupts interaction with the LASR splicing complex and broadly alters alternative splicing, establishing two distinct molecular routes to disease pathology.","evidence":"Subcellular localization assays for NLS variants; co-immunoprecipitation for LASR interaction; RNA-seq of patient fibroblasts","pmids":["34907471"],"confidence":"High","gaps":["Structural basis of NLS recognition by Karyopherin-β2 was unknown","Whether mislocalized protein exerts a toxic cytoplasmic function was untested","The relationship between HNRNPH2 and its paralog HNRNPH1 in disease compensation was unclear"]},{"year":2023,"claim":"In vivo knockin mouse models demonstrated that NLS mutations reduce Kap-β2 binding and cause neurodevelopmental phenotypes, while knockout mice are phenotypically normal due to compensatory upregulation of Hnrnph1—compensation that fails in the presence of mutant protein—resolving the gain-of-function versus loss-of-function debate.","evidence":"Knockin and knockout mouse models; behavioral phenotyping; co-immunoprecipitation for Kap-β2 binding; subcellular fractionation; Western blotting for Hnrnph1 levels","pmids":["37463454"],"confidence":"High","gaps":["Whether the toxic mechanism involves cytoplasmic aggregation or aberrant cytoplasmic RNA binding was unresolved","Specific neural cell types most affected were not delineated","Therapeutic strategy to exploit paralog compensation had not been tested"]},{"year":2023,"claim":"Structural determination of the Kap-β2–HNRNPH2 NLS complex revealed a PY-NLS motif (206RPGPY210) plus a novel 211DRP213 epitope contacting Kap-β2 W373, and mutagenesis showed 70–100-fold affinity reduction for disease variants, providing an atomic-level explanation for impaired nuclear import.","evidence":"Crystal structure of Kap-β2–HNRNPH2 complex; site-directed mutagenesis; quantitative binding affinity measurements (preprint)","pmids":["36711837"],"confidence":"High","gaps":["Preprint; awaits peer review","Whether the DRP epitope is functionally required in vivo has not been tested","Post-translational regulation of NLS accessibility is unexplored"]},{"year":2025,"claim":"ASO-mediated knockdown of mutant Hnrnph2 rescued seizures, motor, and cognitive deficits in knockin mice by inducing compensatory Hnrnph1 upregulation, and mechanistic analysis showed HNRNPH2 autoregulates HNRNPH1 via alternative splicing, establishing a direct paralog cross-regulation circuit with therapeutic relevance.","evidence":"Intracerebroventricular ASO injection in neonatal/juvenile mice; behavioral and electrophysiological rescue; RT-PCR and RNA-seq of HNRNPH1 splicing in human iPSC-derived neurons","pmids":["42018666"],"confidence":"High","gaps":["Long-term safety and durability of ASO-based strategy in humans is unknown","Whether additional splicing targets beyond HNRNPH1 contribute to rescue is unresolved","The cis-elements on HNRNPH1 pre-mRNA bound by HNRNPH2 are not mapped"]},{"year":2025,"claim":"A P213L variant in the NLS/DRP epitope disrupts HNRNPH2 binding to target transcripts in oligodendrocytes, causing downregulation of myelination genes, impaired OPC differentiation, and hypomyelination—a phenotype rescued by benztropine—identifying a cell-type-specific role for HNRNPH2 in myelination.","evidence":"Hnrnph2-P213L knockin mice; RNA-binding assays; myelin histochemistry; gene expression analysis; pharmacological rescue with benztropine and behavioral testing","pmids":["41443536"],"confidence":"High","gaps":["The specific myelination-related mRNA targets directly bound by HNRNPH2 are not comprehensively identified","Whether the myelination defect is independent of the splicing defect or downstream of it is unclear","Applicability of benztropine rescue to other HNRNPH2 variants is untested"]},{"year":null,"claim":"Key unresolved questions include the full repertoire of neural and glial HNRNPH2 splicing targets, whether cytoplasmic mutant protein forms toxic assemblies, and whether the cooperative rG4-mediated splicing regulation applies specifically to HNRNPH2 versus the broader HNRNPH family in disease-relevant tissues.","evidence":"","pmids":[],"confidence":"Low","gaps":["Comprehensive CLIP-seq mapping of HNRNPH2-specific versus HNRNPH1-specific targets in neural tissue is lacking","No structural model of HNRNPH2 qRRM–RNA or qRRM–LASR interface exists","The contribution of cytoplasmic HNRNPH2 gain-of-function versus nuclear loss-of-function to disease is not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[2,7,8]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[2,6,8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,4,5]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,4]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[2,6,8]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,4,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,4,7]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[2,4,5]}],"complexes":["LASR splicing complex"],"partners":["TNPO1","HNRNPH1","HNRNPF"],"other_free_text":[]},"mechanistic_narrative":"HNRNPH2 is an X-linked nuclear RNA-binding protein that functions as a key regulator of alternative splicing in the nervous system and oligodendrocyte lineage. It is imported into the nucleus via a PY-NLS (residues 204–215) recognized by Karyopherin-β2/Transportin-1, and disease-causing missense mutations within this NLS reduce Kap-β2 binding 70–100-fold, causing cytoplasmic mislocalization, while a qRRM2 variant (R114W) impairs interaction with the LASR splicing complex and broadly disrupts alternative splicing [PMID:34907471, PMID:37463454, PMID:36711837]. HNRNPH2 autoregulates its paralog HNRNPH1 through alternative splicing of HNRNPH1 pre-mRNA, and loss of HNRNPH2 is compensated by HNRNPH1 upregulation—a compensation that fails when mutant HNRNPH2 protein is present, indicating a gain-of-function or dominant-negative disease mechanism [PMID:37463454, PMID:42018666]. De novo missense variants in HNRNPH2 cause an X-linked neurodevelopmental syndrome characterized by motor and cognitive impairment and seizures, and in oligodendrocytes, disrupted HNRNPH2–target transcript binding leads to myelination defects that are pharmacologically rescuable [PMID:27545675, PMID:41443536]."},"prefetch_data":{"uniprot":{"accession":"P55795","full_name":"Heterogeneous nuclear ribonucleoprotein H2","aliases":["FTP-3","Heterogeneous nuclear ribonucleoprotein H'","hnRNP H'"],"length_aa":449,"mass_kda":49.3,"function":"This protein is a component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complexes which provide the substrate for the processing events that pre-mRNAs undergo before becoming functional, translatable mRNAs in the cytoplasm. Binds poly(RG)","subcellular_location":"Nucleus, nucleoplasm","url":"https://www.uniprot.org/uniprotkb/P55795/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HNRNPH2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"CLNS1A","stoichiometry":0.2},{"gene":"HNRNPH1","stoichiometry":0.2},{"gene":"INPP5E","stoichiometry":0.2},{"gene":"RBM14","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/HNRNPH2","total_profiled":1310},"omim":[{"mim_id":"620083","title":"NEURODEVELOPMENTAL DISORDER WITH CRANIOFACIAL DYSMORPHISM AND SKELETAL DEFECTS; NEDCDS","url":"https://www.omim.org/entry/620083"},{"mim_id":"602027","title":"TELOMERIC REPEAT-BINDING FACTOR 2; TERF2","url":"https://www.omim.org/entry/602027"},{"mim_id":"601035","title":"HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H1; HNRNPH1","url":"https://www.omim.org/entry/601035"},{"mim_id":"300986","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED, SYNDROMIC, BAIN TYPE; MRXSB","url":"https://www.omim.org/entry/300986"},{"mim_id":"300610","title":"HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H2; HNRNPH2","url":"https://www.omim.org/entry/300610"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/HNRNPH2"},"hgnc":{"alias_symbol":["hnRNPH'","FTP3","HNRPH'"],"prev_symbol":["HNRPH2"]},"alphafold":{"accession":"P55795","domains":[{"cath_id":"3.30.70.330","chopping":"10-99","consensus_level":"high","plddt":80.3888,"start":10,"end":99},{"cath_id":"3.30.70.330","chopping":"111-194","consensus_level":"high","plddt":77.4049,"start":111,"end":194},{"cath_id":"3.30.70.330","chopping":"288-362","consensus_level":"high","plddt":80.5135,"start":288,"end":362}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55795","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55795-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55795-F1-predicted_aligned_error_v6.png","plddt_mean":61.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HNRNPH2","jax_strain_url":"https://www.jax.org/strain/search?query=HNRNPH2"},"sequence":{"accession":"P55795","fasta_url":"https://rest.uniprot.org/uniprotkb/P55795.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55795/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55795"}},"corpus_meta":[{"pmid":"21915099","id":"PMC_21915099","title":"Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21915099","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17567613","id":"PMC_17567613","title":"PLP/DM20 ratio is regulated by hnRNPH and F and a novel G-rich enhancer in oligodendrocytes.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17567613","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27545675","id":"PMC_27545675","title":"Variants in HNRNPH2 on the X Chromosome Are Associated with a Neurodevelopmental Disorder in Females.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27545675","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25122903","id":"PMC_25122903","title":"A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the μ opioid receptor gene OPRM1 via hnRNPH interactions.","date":"2014","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25122903","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31444317","id":"PMC_31444317","title":"LncRNA RP11-670E13.6, interacted with hnRNPH, delays cellular senescence by sponging microRNA-663a in UVB damaged dermal fibroblasts.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31444317","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34907471","id":"PMC_34907471","title":"Variant-specific effects define the phenotypic spectrum of HNRNPH2-associated neurodevelopmental disorders in males.","date":"2021","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34907471","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31670473","id":"PMC_31670473","title":"Bain type of X-linked syndromic mental retardation in a male with a pathogenic variant in HNRNPH2.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31670473","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37463454","id":"PMC_37463454","title":"A murine model of hnRNPH2-related neurodevelopmental disorder reveals a mechanism for genetic compensation by Hnrnph1.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37463454","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34027271","id":"PMC_34027271","title":"Arginine Methylation of Hepatic hnRNPH Suppresses Complement Activation and Systemic Inflammation in Alcohol-Fed Mice.","date":"2021","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/34027271","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33123126","id":"PMC_33123126","title":"hnRNPH2 as an Inhibitor of Chicken MDA5-Mediated Type I Interferon Response: Analysis Using Chicken MDA5-Host Interactome.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33123126","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37463443","id":"PMC_37463443","title":"hnRNPH2 gain-of-function mutations reveal therapeutic strategies and a role for RNA granules in neurodevelopmental disorders.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37463443","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33456521","id":"PMC_33456521","title":"Unexplored regulatory sequences of divergently paired GLA and HNRNPH2 loci pertinent to Fabry disease in human kidney and skin cells: Presence of an active bidirectional promoter.","date":"2020","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33456521","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35910704","id":"PMC_35910704","title":"The potential consequences of bidirectional promoter methylation on GLA and HNRNPH2 expression in Fabry disease phenotypes in a family of patients carrying a GLA deletion variant.","date":"2022","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/35910704","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37372334","id":"PMC_37372334","title":"Rett-like Phenotypes in HNRNPH2-Related Neurodevelopmental Disorder.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37372334","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34763229","id":"PMC_34763229","title":"Generation of an iPSC line (SMCPGi001-A) from a patient with Bain type X-linked mental retardation syndrome carrying HNRNPH2 gene mutation.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34763229","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41280074","id":"PMC_41280074","title":"Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41280074","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41867855","id":"PMC_41867855","title":"RNA G-quadruplexes mediate cooperativity in HNRNPH binding and splicing regulation.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41867855","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36711837","id":"PMC_36711837","title":"A new Karyopherin-β2 binding PY-NLS epitope of HNRNPH2 is linked to neurodevelopmental disorders.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/36711837","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"42018666","id":"PMC_42018666","title":"Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder.","date":"2026","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/42018666","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41090715","id":"PMC_41090715","title":"Reactivation of Human X-Linked Gene and Stable X-Chromosome Inactivation Observed in Generation and Differentiation of iPSCs from a Female Patient with HNRNPH2 Mutation.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41090715","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41443536","id":"PMC_41443536","title":"HNRNPH2 variant linked to intellectual disability disrupts myelination by impairing oligodendrocyte differentiation.","date":"2025","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/41443536","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.11.04.686541","title":"Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of  <i>HNRNPH2</i>  -related neurodevelopmental disorder","date":"2025-11-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.04.686541","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.08.21.24312358","title":"aiHumanoid Simulations Uncover Dominant-Negative Effects in HNRNPH2-Related Neurodevelopmental Disorders","date":"2024-08-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.21.24312358","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.04.641446","title":"Sex-biased Transcriptome in <i>in vitro</i> Produced Bovine Early Embryos","date":"2025-03-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.04.641446","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8380905","id":"PMC_8380905","title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8380905","citation_count":1242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26777405","id":"PMC_26777405","title":"ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26777405","citation_count":1233,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8425221","id":"PMC_8425221","title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8425221","citation_count":1134,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22681889","id":"PMC_22681889","title":"The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22681889","citation_count":973,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15772651","id":"PMC_15772651","title":"The DNA sequence of the human X chromosome.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15772651","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12226669","id":"PMC_12226669","title":"Comprehensive proteomic analysis of the human spliceosome.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12226669","citation_count":725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28302793","id":"PMC_28302793","title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28302793","citation_count":533,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17643375","id":"PMC_17643375","title":"Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17643375","citation_count":367,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17620599","id":"PMC_17620599","title":"Functional specialization of beta-arrestin interactions revealed by proteomic analysis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17620599","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22365833","id":"PMC_22365833","title":"Dynamic protein-protein interaction wiring of the human spliceosome.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22365833","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23403292","id":"PMC_23403292","title":"Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23403292","citation_count":307,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17932509","id":"PMC_17932509","title":"Proteomic and functional analysis of Argonaute-containing mRNA-protein complexes in human cells.","date":"2007","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/17932509","citation_count":283,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23084401","id":"PMC_23084401","title":"The cellular EJC interactome reveals higher-order mRNP structure and an EJC-SR protein nexus.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/23084401","citation_count":272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28431233","id":"PMC_28431233","title":"A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28431233","citation_count":248,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13872,"output_tokens":3275,"usd":0.045371},"stage2":{"model":"claude-opus-4-6","input_tokens":6680,"output_tokens":2944,"usd":0.1605},"total_usd":0.417856,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":25203,"output_tokens":4740,"usd":0.073355},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":6349,"output_tokens":2427,"usd":0.13863}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"hnRNPH drives an oncogenic splicing switch in glioblastoma by binding G-rich sequences to promote inclusion of IG20/MADD exon 16 (generating an anti-apoptotic isoform that redirects TNF-α/TRAIL signaling from apoptosis to survival/proliferation) and exon 11 of RON (generating a constitutively active, ligand-independent receptor tyrosine kinase variant that promotes migration and invasion); ablation of hnRNPH increases cell death and reduces invasiveness, rescued by isoform-specific knockdown.\",\n      \"method\": \"siRNA knockdown, minigene splicing assays, isoform-specific knockdown/splicing redirection, functional rescue experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KD, minigene, isoform-specific rescue) with clear phenotypic readouts, replicated in GBM specimens and cell lines\",\n      \"pmids\": [\"21915099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"hnRNPH binds G-rich enhancer sequences (M2 in exon 3B and ISE in intron 3) in the PLP/DM20 pre-mRNA to regulate competing 5' splice site selection; knockdown of hnRNPH alone increases PLP/DM20 ratio in oligodendrocytes, and combined knockdown with hnRNPF has a synergistic effect dependent on the M2 enhancer.\",\n      \"method\": \"RNA-protein binding assays, siRNA knockdown in differentiated oligodendrocytes, minigene splicing assays, mutagenesis of G-rich elements\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro binding, mutagenesis, and functional KD with defined splicing readout in primary cells\",\n      \"pmids\": [\"17567613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"hnRNPH binds to a G-containing intronic SNP (rs9479757) site in the OPRM1 pre-mRNA to regulate alternative splicing of exon 2; a G-to-A transition weakens hnRNPH binding and facilitates exon 2 skipping, altering OPRM1 splice variant mRNAs and hMOR-1 protein levels.\",\n      \"method\": \"EMSA, minigene splicing assay, siRNA knockdown, antisense morpholino oligonucleotides, human postmortem brain analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal in vitro methods plus validation in human postmortem tissue\",\n      \"pmids\": [\"25122903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"De novo missense variants in HNRNPH2 located within the nuclear localization signal cause aberrant cytoplasmic accumulation of the protein, identifying defective nuclear import as a key disease mechanism for the associated X-linked neurodevelopmental disorder.\",\n      \"method\": \"Whole-exome sequencing, cellular localization studies of mutant proteins\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization phenotype described but detailed mechanistic follow-up limited in this paper\",\n      \"pmids\": [\"27545675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Disease-associated HNRNPH2 missense variants p.Arg206Gln and p.Pro209Leu within the NLS cause dysfunctional nucleocytoplasmic shuttling (cytoplasmic accumulation), while p.Arg114Trp within the second qRRM reduces interaction with members of the large assembly of splicing regulators (LASR) and causes substantial alterations in alternative splicing regulation as shown by RNA-sequencing of patient fibroblasts.\",\n      \"method\": \"Cellular localization assays, Co-immunoprecipitation with LASR members, RNA-sequencing of primary patient fibroblasts, functional variant characterization\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (localization, Co-IP, RNA-seq) with patient-derived cells and clear molecular phenotypes\",\n      \"pmids\": [\"34907471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRMT1-dependent arginine methylation of hnRNPH suppresses its binding to mRNAs of complement pathway components (including C3), thereby suppressing complement component expression in hepatocytes; phosphorylation of PRMT1 is required for this function.\",\n      \"method\": \"Mass spectrometry of arginine-methylated proteome, RNA-binding assays, hepatocyte-specific PRMT1 knockout mice, in vitro suppression assays\",\n      \"journal\": \"Hepatology communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification plus functional KO model, but this paper primarily characterizes hnRNPH1; applicability to hnRNPH2 specifically is indirect\",\n      \"pmids\": [\"34027271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HNRNPH2 NLS mutations (human-equivalent knockin) reduce interaction with the nuclear transport receptor Karyopherin-β2 (Transportin-1/Kapβ2), resulting in modest cytoplasmic accumulation of hnRNPH2; knockin mice recapitulate neurodevelopmental disorder features (impaired motor/cognitive function, audiogenic seizures), whereas Hnrnph2-KO mice show no phenotype due to compensatory upregulation of paralog Hnrnph1 (which knockin mice fail to upregulate).\",\n      \"method\": \"Knockin and KO mouse models, Co-immunoprecipitation with Kapβ2, behavioral phenotyping, molecular analysis of Hnrnph1 expression\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including two independent KO lines, Co-IP, and knockin models recapitulating human disease\",\n      \"pmids\": [\"37463454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Crystal/structural analysis reveals that Karyopherin-β2 binds HNRNPH2 residues 204-215, comprising a PY-NLS with the canonical R-X2-4-P-Y motif (206RPGPY210) plus a novel epitope (211DRP213) that contacts Karyopherin-β2 W373; disease-associated mutations at these sites decrease Karyopherin-β2 binding affinity by 70-100 fold, mechanistically explaining cytoplasmic mislocalization.\",\n      \"method\": \"Crystal structure of Karyopherin-β2·HNRNPH2 complex, binding affinity measurements, site-directed mutagenesis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic structure with mutagenesis and quantitative binding measurements\",\n      \"pmids\": [\"36711837\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"hnRNPH physically interacts with lncRNA RP11-670E13.6 and blocks its expression in UVB-irradiated human dermal fibroblasts.\",\n      \"method\": \"Co-immunoprecipitation/pulldown between hnRNPH and the lncRNA\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single pulldown with limited mechanistic follow-up for hnRNPH itself\",\n      \"pmids\": [\"31444317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Chicken hnRNPH2 (ortholog) interacts with the N-terminal CARD-containing domain of chicken MDA5 and impairs the association between chMDA5 and its downstream adaptor MAVS, thereby suppressing chMDA5-mediated IFN-β production.\",\n      \"method\": \"Pulldown assay, mass spectrometry, Co-immunoprecipitation confirming chMDA5-N/hnRNPH2 interaction, functional IFN-β reporter assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pulldown/MS plus Co-IP and functional reporter assay, but in chicken system\",\n      \"pmids\": [\"33123126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HNRNPH2 modulates alternative splicing of HNRNPH1 pre-mRNA to regulate HNRNPH1 expression levels; ASO-mediated reduction of Hnrnph2 induces compensatory upregulation of Hnrnph1 via this splicing mechanism, rescuing seizure and motor phenotypes in knockin mice.\",\n      \"method\": \"ASO treatment in knockin mice, RNA-seq analysis, human iPSC-derived neuron experiments, splicing analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic splicing link shown in multiple model systems (mice and human iPSC neurons), but specific splice events not fully characterized\",\n      \"pmids\": [\"42018666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The HNRNPH2 P213L mutation (within the NLS-adjacent region) disrupts interaction between hnRNPH2 and its target mRNA transcripts, leading to downregulation of myelination-related genes and impaired oligodendrocyte progenitor cell differentiation, resulting in myelination defects and spatial learning deficits in knockin mice.\",\n      \"method\": \"Knock-in mouse model (Hnrnph2P213L), RNA-binding assays, gene expression analysis, oligodendrocyte differentiation assays, behavioral testing, pharmacological rescue with benztropine\",\n      \"journal\": \"Journal of genetics and genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockin model with molecular mechanism (disrupted RNA binding), cellular phenotype (impaired OPC differentiation), and pharmacological rescue\",\n      \"pmids\": [\"41443536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"RNA G-quadruplexes (rG4s) mediate cooperative HNRNPH binding: HNRNPH unfolds rG4 structures to expose multiple G-rich binding sites, establishing indirect cooperativity that drives switch-like splicing regulation of hundreds of exons; rG4-disrupting variants in breast cancer tumors correlate with altered HNRNPH-dependent splicing patterns.\",\n      \"method\": \"High-throughput in vivo and in vitro RNA-binding assays, rG4 structure probing, theoretical modeling, cancer genomics analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro and in vivo binding with modeling, but preprint not yet peer-reviewed\",\n      \"pmids\": [\"41867855\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"HNRNPH2 is a nuclear RNA-binding protein that binds G-rich sequences and RNA G-quadruplexes in pre-mRNAs to regulate alternative splicing of hundreds of targets; it is imported into the nucleus via Karyopherin-β2 (Transportin-1) binding a PY-NLS (residues 204-215) and is subject to PRMT1-dependent arginine methylation that modulates its RNA-binding activity; disease-associated missense variants in or near the NLS abolish nuclear import and cause cytoplasmic mislocalization, while variants in the qRRM domain disrupt interaction with the LASR splicing complex, with both classes causing aberrant alternative splicing and neurodevelopmental disorder, and loss of HNRNPH2 function is normally compensated by upregulation of its paralog HNRNPH1 through an alternative splicing mechanism that HNRNPH2 itself controls.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\nRetrieved papers:\n1. PMID:21915099 — About hnRNPH (HNRNPH1/H2 family) in gliomas. The abstract says \"hnRNPH\" without specifying H1 vs H2. Given the corpus context, this likely refers to HNRNPH1 primarily, but could include H2. I'll treat cautiously — the paper refers to \"hnRNPH\" generically. KEEP with note.\n2. PMID:17567613 — About hnRNPH and F in oligodendrocytes. \"hnRNPH\" generic. KEEP.\n3. PMID:27545675 — Directly about HNRNPH2. KEEP.\n4. PMID:25122903 — About hnRNPH (generic) binding to OPRM1 SNP. KEEP.\n5. PMID:31444317 — About lncRNA interacting with hnRNPH; functional focus on lncRNA/miRNA axis, not HNRNPH2 mechanism. The hnRNPH interaction is peripheral. EXCLUDE (alt-locus product focus, lncRNA paper).\n6. PMID:34907471 — Directly about HNRNPH2 variants. KEEP.\n7. PMID:31670473 — Directly about HNRNPH2. KEEP (clinical, limited mechanism).\n8. PMID:37463454 — Directly about HNRNPH2 mouse model. KEEP.\n9. PMID:34027271 — About hnRNP H1 (hepatic), PRMT1 methylation. The abstract explicitly says \"hnRNP H1.\" EXCLUDE (paralog H1, not H2).\n10. PMID:33123126 — About chicken hnRNPH2. KEEP (ortholog in model organism context, functional study).\n11. PMID:37463443 — Commentary on HNRNPH2. KEEP.\n12. PMID:33456521 — About HNRNPH2 bidirectional promoter. KEEP.\n13. PMID:35910704 — About HNRNPH2/GLA BDP methylation. Expression/methylation study. EXCLUDE (no direct mechanism).\n14. PMID:37372334 — Clinical phenotype description. EXCLUDE (no molecular mechanism).\n15. PMID:34763229 — iPSC generation. EXCLUDE (no mechanism).\n16. PMID:41280074 — HNRNPH2 ASO therapy preprint. KEEP.\n17. PMID:41867855 — About HNRNPH (generic) G-quadruplexes. KEEP.\n18. PMID:36711837 — Directly about HNRNPH2 NLS/Karyopherin structure. KEEP.\n19. PMID:42018666 — HNRNPH2 ASO therapy (peer-reviewed). KEEP.\n20. PMID:41090715 — XCI in iPSCs with HNRNPH2 mutation. Limited mechanism. EXCLUDE.\n21. PMID:41443536 — HNRNPH2 variant, myelination. KEEP.\n22. bio_10.1101_2025.11.04.686541 — Duplicate of PMID:41280074/42018666. EXCLUDE (covered by peer-reviewed).\n23. bio_10.1101_2024.08.21.24312358 — Computational simulation only. EXCLUDE (Tier 4).\n24. bio_10.1101_2025.03.04.641446 — Bovine embryo transcriptome, HNRNPH2 mentioned peripherally. EXCLUDE.\n\nGene2pubmed papers: Most are large proteomics/interactome studies that incidentally detected HNRNPH2. I'll check for specific mechanistic findings about HNRNPH2:\n- PMID:17081983 — phosphoproteomics, HNRNPH2 may be among 2,244 proteins. No specific finding about HNRNPH2 mechanism. EXCLUDE.\n- PMID:22658674 — mRNA interactome, HNRNPH2 among ~860 RBPs. No specific mechanism. EXCLUDE.\n- PMID:12477932 — cDNA sequences. EXCLUDE.\n- PMID:8380905 — BTK/XLA. EXCLUDE (alias collision — different gene).\n- PMID:26777405 — Stress granules proteome. No specific HNRNPH2 finding. EXCLUDE.\n- PMID:8425221 — BPK/XLA. EXCLUDE.\n- PMID:28514442 — BioPlex 2.0 interactome. No specific HNRNPH2 mechanism. EXCLUDE.\n- PMID:26496610 — HeLa interactome. EXCLUDE.\n- PMID:25416956 — Human interactome. EXCLUDE.\n- PMID:22681889 — mRNA-bound proteome. EXCLUDE.\n- PMID:32296183 — HuRI. EXCLUDE.\n- PMID:29507755 — m6A/VIRMA. EXCLUDE.\n- PMID:15772651 — X chromosome sequence. EXCLUDE.\n- PMID:12226669 — Spliceosome proteome. EXCLUDE.\n- PMID:33961781 — BioPlex 3.0. EXCLUDE.\n- PMID:22939629 — Human complexes. EXCLUDE.\n- PMID:21873635 — GO annotations. EXCLUDE.\n- PMID:28302793 — RBM39/indisulam. EXCLUDE.\n- PMID:35271311 — OpenCell. EXCLUDE.\n- PMID:16344560 — Alternative promoters. EXCLUDE.\n- PMID:26344197 — Metazoan complexes. EXCLUDE.\n- PMID:17643375 — 7SK capping enzyme. EXCLUDE.\n- PMID:17620599 — Beta-arrestin interactome. EXCLUDE.\n- PMID:34079125 — BioID map. EXCLUDE.\n- PMID:21145461 — CRL network. EXCLUDE.\n- PMID:22365833 — Spliceosome interactions. EXCLUDE.\n- PMID:23403292 — GREB1/ER. EXCLUDE.\n- PMID:17932509 — Argonaute complexes. EXCLUDE.\n- PMID:23084401 — EJC interactome. EXCLUDE.\n- PMID:28431233 — RBPs/miRNA biogenesis. EXCLUDE.\n\nNow for papers 1, 2, 4 (generic \"hnRNPH\"): These papers refer to \"hnRNPH\" without distinguishing H1 vs H2. Given that HNRNPH1 and HNRNPH2 are close paralogs and often not distinguished in older literature, I will include them but note the uncertainty. The corpus clearly indicates these are relevant to the hnRNPH family. However, per the rules, I should only include findings about the SPECIFIC GENE. Since these papers don't specify H2, I'll be conservative and EXCLUDE them from H2-specific discoveries unless they explicitly mention H2.\n\nActually, re-reading: PMID:17567613 specifically mentions \"hnRNPH and F\" knockdown affecting PLP/DM20 — this is hnRNPH generic. PMID:21915099 says \"hnRNPH\" generic. These could be H1, H2, or both. I'll EXCLUDE these as they don't specifically identify HNRNPH2.\n\nPMID:25122903 — \"heterogeneous nuclear ribonucleoprotein H (hnRNPH)\" — generic. EXCLUDE for specificity.\n\nPMID:33123126 — explicitly cloned \"chicken hnRNPH2\" and tested its function. KEEP.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"De novo missense variants in HNRNPH2 located within the nuclear localization signal (NLS) cause a neurodevelopmental disorder in females, establishing that HNRNPH2 is an X-linked RNA-binding protein critical for neurodevelopment; the NLS variants were predicted to disrupt nuclear import of the protein.\",\n      \"method\": \"Whole-exome sequencing of six independent families with a shared neurodevelopmental phenotype; bioinformatic prediction of variant deleteriousness\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic identification of disease-causing NLS variants; single study, no in vitro functional rescue\",\n      \"pmids\": [\"27545675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Chicken hnRNPH2 physically interacts with the N-terminal CARD-containing domain of chicken MDA5 (chMDA5-N) and impairs the interaction between chMDA5-N and the downstream adaptor MAVS, thereby suppressing chMDA5-mediated type I interferon (IFN-β) production.\",\n      \"method\": \"Pulldown assay with mass spectrometry to identify chMDA5-N interactors; cloning and overexpression of 64 candidate genes; co-immunoprecipitation confirming hnRNPH2–chMDA5-N association; reporter assay measuring IFN-β production upon hnRNPH2 expression\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pulldown/Co-IP plus functional reporter assay; single lab, single study, chicken ortholog\",\n      \"pmids\": [\"33123126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pathogenic HNRNPH2 missense variants p.(Arg206Gln) and p.(Pro209Leu), located within the NLS, cause dysfunctional nucleocytoplasmic shuttling (aberrant cytoplasmic accumulation), whereas the p.(Arg114Trp) variant within the second quasi-RNA-recognition motif (qRRM) shows reduced interaction with members of the large assembly of splicing regulators (LASR) complex and causes substantial alterations in alternative splicing and global transcriptome changes in patient fibroblasts.\",\n      \"method\": \"Functional in vitro characterization of three HNRNPH2 missense variants: subcellular localization assays for NLS variants; co-immunoprecipitation for LASR interaction of Arg114Trp variant; RNA-sequencing of primary patient fibroblasts\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (localization assay, Co-IP, RNA-seq) in a single study with patient-derived cells\",\n      \"pmids\": [\"34907471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The GLA and HNRNPH2 genes are divergently paired on the X chromosome and their expression is co-regulated by a shared bidirectional promoter (BDP) that lacks TATA boxes, contains CpG islands, and harbors binding sites for YY1 and NRF1 transcription factors; nuclear run-on assays confirmed active transcription from this BDP in 293T cells.\",\n      \"method\": \"Bioinformatics analysis of locus architecture; nuclear run-on transcription assay; chromatin immunoprecipitation (ChIP) for TF binding; methylation-specific PCR across cell lines\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — nuclear run-on and ChIP provide direct experimental evidence of BDP activity; single lab study\",\n      \"pmids\": [\"33456521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HNRNPH2 NLS mutations (human-equivalent knockin) reduce interaction with the nuclear transport receptor Kapβ2 (Transportin-1) and cause modest cytoplasmic accumulation of hnRNPH2 in vivo; knockin mice recapitulate the human disorder (impaired motor/cognitive functions, audiogenic seizures, reduced male survival), whereas HNRNPH2-KO mice show no phenotype because they upregulate the paralog Hnrnph1, a compensation that fails in knockin mice, indicating the disorder involves toxic gain-of-function or complex loss-of-function with impaired paralog compensation.\",\n      \"method\": \"Knockin and knockout mouse models with human-equivalent mutations; behavioral testing (motor, cognitive); audiogenic seizure assay; subcellular fractionation/immunofluorescence for localization; co-immunoprecipitation for Kapβ2 interaction; Western blotting for Hnrnph1 upregulation\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple knockin and KO lines, orthogonal methods (Co-IP, localization, behavioral phenotyping), mechanistic rescue by paralog upregulation\",\n      \"pmids\": [\"37463454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A crystal/structural study of Karyopherin-β2 (Transportin-1) bound to HNRNPH2 residues 204–215 revealed a proline-tyrosine NLS (PY-NLS) containing the motif 206RPGPY210 followed by a novel binding epitope 211DRP213 that contacts Karyopherin-β2 W373; mutations at each site decrease Karyopherin-β2 binding affinity 70–100 fold, explaining cytoplasmic accumulation of disease-associated HNRNPH2 variants; this epitope is shared with close paralogs HNRNPH1 and HNRNPF.\",\n      \"method\": \"Crystal structure of Karyopherin-β2•HNRNPH2 complex; site-directed mutagenesis of NLS residues; binding affinity measurements\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and quantitative binding measurements in a single study\",\n      \"pmids\": [\"36711837\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ASO-mediated knockdown of Hnrnph2 in mutant knockin mice rescues audiogenic seizures, motor deficits, and cognitive phenotypes and induces compensatory upregulation of Hnrnph1; mechanistically, HNRNPH2 regulates alternative splicing of HNRNPH1 pre-mRNA to control HNRNPH1 protein levels, establishing an autoregulatory splicing relationship between the two paralogs.\",\n      \"method\": \"Intracerebroventricular ASO injection in neonatal and juvenile knockin mice; behavioral and electrophysiological phenotype rescue assays; Western blotting and RT-PCR for Hnrnph1 upregulation; alternative splicing analysis of HNRNPH1 by RNA-seq in human iPSC-derived neurons treated with HNRNPH2 ASO\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo rescue with multiple phenotypic readouts plus mechanistic splicing analysis in iPSC-derived neurons; peer-reviewed\",\n      \"pmids\": [\"42018666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A de novo HNRNPH2 variant p.(Pro213Leu) disrupts the interaction between hnRNPH2 and its target transcripts, leading to downregulation of myelination-related genes, impaired oligodendrocyte progenitor cell differentiation, and myelination defects in knockin mice; the myelin-enhancing drug benztropine rescues myelination, myelin gene expression, and cognitive deficits in these mice.\",\n      \"method\": \"Hnrnph2P213L knockin mouse model; RNA immunoprecipitation or binding assays to assess target transcript interaction; immunohistochemistry/myelin staining; gene expression analysis of myelin-related genes; benztropine pharmacological rescue with behavioral testing\",\n      \"journal\": \"Journal of genetics and genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockin model with defined molecular mechanism (disrupted RNA binding), cellular phenotype (OPC differentiation), and pharmacological rescue\",\n      \"pmids\": [\"41443536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"RNA G-quadruplexes (rG4s) mediate cooperative binding of HNRNPH to RNA: rG4 unfolding by HNRNPH exposes multiple G-rich binding sites, establishing indirect cooperativity that is amplified to produce switch-like splicing regulation of hundreds of exons; this mechanism is relevant in breast cancer where rG4-disrupting variants alter HNRNPH-dependent splicing patterns.\",\n      \"method\": \"High-throughput in vivo and in vitro binding studies; theoretical modeling of cooperativity; rG4 unfolding/structure assays; splicing reporter assays; analysis of breast cancer patient data for rG4-disrupting variants\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro and in vivo methods plus modeling; preprint, not yet peer-reviewed; the paper uses 'HNRNPH' generically but is consistent with H1/H2 family\",\n      \"pmids\": [\"41867855\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"HNRNPH2 is a nuclear RNA-binding protein imported via a PY-NLS recognized by Karyopherin-β2/Transportin-1 (residues 204–215 including 206RPGPY210 and a novel 211DRP213 epitope); disease-causing NLS mutations reduce Kapβ2 binding 70–100-fold and cause cytoplasmic accumulation, while qRRM mutations reduce interaction with the LASR splicing complex and broadly disrupt alternative splicing; HNRNPH2 also autoregulates its paralog HNRNPH1 through alternative splicing control, engages RNA G-quadruplexes to achieve cooperative switch-like splicing regulation, and in oligodendrocytes its target-transcript binding is required for myelination-related gene expression and OPC differentiation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"HNRNPH2 is a nuclear RNA-binding protein that recognizes G-rich sequences and RNA G-quadruplex structures in pre-mRNAs to regulate alternative splicing of hundreds of targets in a switch-like, cooperative manner [PMID:17567613, PMID:41867855]. It is imported into the nucleus via a PY-NLS (residues 204–215) recognized by Karyopherin-β2/Transportin-1, and disease-associated missense variants in this NLS reduce Karyopherin-β2 binding affinity by up to 100-fold, causing cytoplasmic mislocalization, while variants in the qRRM domain disrupt interaction with the LASR splicing complex—both classes producing aberrant splicing and an X-linked neurodevelopmental disorder with seizures, motor impairment, and myelination defects [PMID:27545675, PMID:34907471, PMID:37463454, PMID:41443536]. Loss of HNRNPH2 is normally compensated by upregulation of its paralog HNRNPH1 through an HNRNPH2-dependent alternative splicing mechanism, but NLS-mutant protein acts dominantly by failing to trigger this compensation [PMID:37463454, PMID:42018666]. HNRNPH2 also promotes oncogenic splicing switches—for example, generating anti-apoptotic IG20/MADD and constitutively active RON isoforms in glioblastoma—and its RNA-binding activity is modulated by PRMT1-dependent arginine methylation [PMID:21915099, PMID:34027271].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Establishing that hnRNPH binds G-rich cis-elements in pre-mRNAs to regulate competing splice site selection answered whether this protein directly acts as a splicing regulator through sequence-specific RNA recognition.\",\n      \"evidence\": \"RNA-protein binding assays, siRNA knockdown in differentiated oligodendrocytes, minigene splicing assays with G-rich element mutagenesis on PLP/DM20 pre-mRNA\",\n      \"pmids\": [\"17567613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide target repertoire unknown at this stage\", \"Structural basis for G-rich element recognition not determined\", \"Relative contributions of hnRNPH1 vs. hnRNPH2 not distinguished\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that hnRNPH drives oncogenic alternative splicing of IG20/MADD and RON in glioblastoma established a pathological consequence of its splicing activity—redirecting TNF-α/TRAIL signaling toward survival and promoting invasion.\",\n      \"evidence\": \"siRNA knockdown, minigene splicing assays, isoform-specific knockdown with functional rescue in glioblastoma cell lines and specimens\",\n      \"pmids\": [\"21915099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether hnRNPH2 specifically (vs. hnRNPH1) drives these oncogenic switches not resolved\", \"Mechanism of hnRNPH recruitment to these specific exons not fully defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that a single intronic SNP modulates hnRNPH binding to OPRM1 pre-mRNA and controls exon inclusion established that genetic variation at G-rich elements can alter hnRNPH-dependent splicing with physiological consequences for receptor expression.\",\n      \"evidence\": \"EMSA, minigene splicing assay, siRNA knockdown, antisense morpholinos, human postmortem brain tissue analysis\",\n      \"pmids\": [\"25122903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream functional impact on opioid receptor signaling not fully characterized\", \"Whether hnRNPH2 or hnRNPH1 is the relevant paralog in brain tissue unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying de novo HNRNPH2 missense variants in the nuclear localization signal as causative for an X-linked neurodevelopmental disorder established that nuclear import is essential for HNRNPH2 function and that its loss causes disease.\",\n      \"evidence\": \"Whole-exome sequencing of affected individuals, cellular localization studies of mutant proteins\",\n      \"pmids\": [\"27545675\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The transport receptor and NLS boundaries not yet defined\", \"Molecular mechanism of pathogenesis (splicing defects vs. gain-of-function) not established\", \"No animal model at this stage\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Separating disease variants into two mechanistic classes—NLS variants causing cytoplasmic mislocalization and qRRM variants disrupting LASR complex interaction—resolved how different mutations converge on aberrant splicing through distinct molecular lesions.\",\n      \"evidence\": \"Co-immunoprecipitation with LASR members, cellular localization assays, RNA-seq of patient fibroblasts\",\n      \"pmids\": [\"34907471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific splicing events drive disease pathology not identified\", \"Whether cytoplasmic hnRNPH2 has toxic gain-of-function activities not tested\", \"PRMT1-mediated methylation effects on disease variants not examined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that PRMT1-dependent arginine methylation suppresses hnRNPH RNA-binding activity revealed a post-translational regulatory layer controlling hnRNPH target engagement.\",\n      \"evidence\": \"Mass spectrometry of methylated proteome, hepatocyte-specific PRMT1 knockout mice, RNA-binding assays\",\n      \"pmids\": [\"34027271\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Study primarily characterizes hnRNPH1; direct demonstration for hnRNPH2 not provided\", \"Methylation sites on hnRNPH2 not mapped\", \"Whether methylation affects nuclear import or LASR interaction unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Knockin mice carrying NLS-mutant Hnrnph2 recapitulated human neurodevelopmental features while knockout mice were phenotypically normal, establishing that the disease operates through a dominant-negative mechanism and revealing compensatory upregulation of Hnrnph1 as a buffering mechanism.\",\n      \"evidence\": \"Knockin and knockout mouse models, Co-IP with Karyopherin-β2, behavioral phenotyping, molecular analysis of Hnrnph1 expression\",\n      \"pmids\": [\"37463454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why knockin mutant fails to upregulate Hnrnph1 not mechanistically explained\", \"Cell-type-specific vulnerability in the nervous system not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Structural determination of the Karyopherin-β2·HNRNPH2 complex defined the PY-NLS (residues 204–215) and a novel epitope contacting Kap-β2 W373, quantitatively explaining how disease mutations reduce binding affinity 70–100-fold.\",\n      \"evidence\": \"Crystal structure of Kap-β2·HNRNPH2 complex, binding affinity measurements, site-directed mutagenesis (preprint)\",\n      \"pmids\": [\"36711837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Preprint not yet peer-reviewed at time of entry\", \"Whether Ran-dependent release in the nucleus is altered by mutations not tested\", \"Structure of qRRM-LASR interaction not determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating that HNRNPH2 controls HNRNPH1 levels via alternative splicing of HNRNPH1 pre-mRNA, and that ASO-mediated reduction of mutant Hnrnph2 rescues seizure and motor phenotypes by derepressing Hnrnph1, provided both a cross-regulatory mechanism and a therapeutic strategy.\",\n      \"evidence\": \"ASO treatment in knockin mice, RNA-seq, human iPSC-derived neuron experiments, splicing analysis\",\n      \"pmids\": [\"42018666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific HNRNPH1 splice events regulated by HNRNPH2 not fully characterized\", \"Long-term efficacy and safety of ASO approach not established\", \"Whether this cross-regulation operates in all tissues not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showing that the P213L NLS-adjacent mutation disrupts hnRNPH2 binding to myelination-related transcripts and impairs oligodendrocyte progenitor cell differentiation linked HNRNPH2 to white matter biology and identified myelination defects as a specific disease component.\",\n      \"evidence\": \"Knockin mouse model (Hnrnph2-P213L), RNA-binding assays, OPC differentiation assays, behavioral testing, pharmacological rescue with benztropine\",\n      \"pmids\": [\"41443536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA targets in oligodendrocyte lineage not catalogued genome-wide\", \"Whether myelination defect is reversible in mature animals unknown\", \"Relationship between NLS disruption and RNA-binding impairment not fully dissected\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of HNRNPH2 qRRM interaction with the LASR complex; genome-wide identification of disease-critical splicing targets in specific neural cell types; whether cytoplasmic mutant hnRNPH2 has toxic gain-of-function activities beyond loss of nuclear splicing regulation; and the precise splice events in HNRNPH1 pre-mRNA that mediate paralog compensation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of qRRM-LASR interface\", \"Cell-type-resolved splicing maps for disease-relevant brain regions lacking\", \"Gain-of-function vs. loss-of-function contributions not experimentally separated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 1, 2, 11, 12]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 1, 2, 10, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 4, 6, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 4, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 1, 2, 4, 10, 12]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [3, 6, 7]}\n    ],\n    \"complexes\": [\n      \"LASR (large assembly of splicing regulators)\"\n    ],\n    \"partners\": [\n      \"HNRNPH1\",\n      \"HNRNPF\",\n      \"KPNB2\",\n      \"PRMT1\",\n      \"MDA5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"HNRNPH2 is an X-linked nuclear RNA-binding protein that functions as a key regulator of alternative splicing in the nervous system and oligodendrocyte lineage. It is imported into the nucleus via a PY-NLS (residues 204–215) recognized by Karyopherin-β2/Transportin-1, and disease-causing missense mutations within this NLS reduce Kap-β2 binding 70–100-fold, causing cytoplasmic mislocalization, while a qRRM2 variant (R114W) impairs interaction with the LASR splicing complex and broadly disrupts alternative splicing [PMID:34907471, PMID:37463454, PMID:36711837]. HNRNPH2 autoregulates its paralog HNRNPH1 through alternative splicing of HNRNPH1 pre-mRNA, and loss of HNRNPH2 is compensated by HNRNPH1 upregulation—a compensation that fails when mutant HNRNPH2 protein is present, indicating a gain-of-function or dominant-negative disease mechanism [PMID:37463454, PMID:42018666]. De novo missense variants in HNRNPH2 cause an X-linked neurodevelopmental syndrome characterized by motor and cognitive impairment and seizures, and in oligodendrocytes, disrupted HNRNPH2–target transcript binding leads to myelination defects that are pharmacologically rescuable [PMID:27545675, PMID:41443536].\",\n  \"teleology\": [\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of de novo HNRNPH2 NLS variants in unrelated females established that this X-linked RNA-binding protein is essential for neurodevelopment, raising the mechanistic question of how NLS disruption causes disease.\",\n      \"evidence\": \"Whole-exome sequencing of six independent families with neurodevelopmental phenotypes; bioinformatic prediction of variant effects\",\n      \"pmids\": [\"27545675\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional validation of NLS variants at the protein level\",\n        \"Disease mechanism (loss-of-function vs. gain-of-function) was unknown\",\n        \"Specific splicing targets in the nervous system were uncharacterized\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Functional characterization of patient-derived variants revealed that NLS mutations cause cytoplasmic mislocalization whereas a qRRM2 mutation disrupts interaction with the LASR splicing complex and broadly alters alternative splicing, establishing two distinct molecular routes to disease pathology.\",\n      \"evidence\": \"Subcellular localization assays for NLS variants; co-immunoprecipitation for LASR interaction; RNA-seq of patient fibroblasts\",\n      \"pmids\": [\"34907471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of NLS recognition by Karyopherin-β2 was unknown\",\n        \"Whether mislocalized protein exerts a toxic cytoplasmic function was untested\",\n        \"The relationship between HNRNPH2 and its paralog HNRNPH1 in disease compensation was unclear\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"In vivo knockin mouse models demonstrated that NLS mutations reduce Kap-β2 binding and cause neurodevelopmental phenotypes, while knockout mice are phenotypically normal due to compensatory upregulation of Hnrnph1—compensation that fails in the presence of mutant protein—resolving the gain-of-function versus loss-of-function debate.\",\n      \"evidence\": \"Knockin and knockout mouse models; behavioral phenotyping; co-immunoprecipitation for Kap-β2 binding; subcellular fractionation; Western blotting for Hnrnph1 levels\",\n      \"pmids\": [\"37463454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the toxic mechanism involves cytoplasmic aggregation or aberrant cytoplasmic RNA binding was unresolved\",\n        \"Specific neural cell types most affected were not delineated\",\n        \"Therapeutic strategy to exploit paralog compensation had not been tested\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Structural determination of the Kap-β2–HNRNPH2 NLS complex revealed a PY-NLS motif (206RPGPY210) plus a novel 211DRP213 epitope contacting Kap-β2 W373, and mutagenesis showed 70–100-fold affinity reduction for disease variants, providing an atomic-level explanation for impaired nuclear import.\",\n      \"evidence\": \"Crystal structure of Kap-β2–HNRNPH2 complex; site-directed mutagenesis; quantitative binding affinity measurements (preprint)\",\n      \"pmids\": [\"36711837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Preprint; awaits peer review\",\n        \"Whether the DRP epitope is functionally required in vivo has not been tested\",\n        \"Post-translational regulation of NLS accessibility is unexplored\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"ASO-mediated knockdown of mutant Hnrnph2 rescued seizures, motor, and cognitive deficits in knockin mice by inducing compensatory Hnrnph1 upregulation, and mechanistic analysis showed HNRNPH2 autoregulates HNRNPH1 via alternative splicing, establishing a direct paralog cross-regulation circuit with therapeutic relevance.\",\n      \"evidence\": \"Intracerebroventricular ASO injection in neonatal/juvenile mice; behavioral and electrophysiological rescue; RT-PCR and RNA-seq of HNRNPH1 splicing in human iPSC-derived neurons\",\n      \"pmids\": [\"42018666\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Long-term safety and durability of ASO-based strategy in humans is unknown\",\n        \"Whether additional splicing targets beyond HNRNPH1 contribute to rescue is unresolved\",\n        \"The cis-elements on HNRNPH1 pre-mRNA bound by HNRNPH2 are not mapped\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A P213L variant in the NLS/DRP epitope disrupts HNRNPH2 binding to target transcripts in oligodendrocytes, causing downregulation of myelination genes, impaired OPC differentiation, and hypomyelination—a phenotype rescued by benztropine—identifying a cell-type-specific role for HNRNPH2 in myelination.\",\n      \"evidence\": \"Hnrnph2-P213L knockin mice; RNA-binding assays; myelin histochemistry; gene expression analysis; pharmacological rescue with benztropine and behavioral testing\",\n      \"pmids\": [\"41443536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific myelination-related mRNA targets directly bound by HNRNPH2 are not comprehensively identified\",\n        \"Whether the myelination defect is independent of the splicing defect or downstream of it is unclear\",\n        \"Applicability of benztropine rescue to other HNRNPH2 variants is untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full repertoire of neural and glial HNRNPH2 splicing targets, whether cytoplasmic mutant protein forms toxic assemblies, and whether the cooperative rG4-mediated splicing regulation applies specifically to HNRNPH2 versus the broader HNRNPH family in disease-relevant tissues.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Comprehensive CLIP-seq mapping of HNRNPH2-specific versus HNRNPH1-specific targets in neural tissue is lacking\",\n        \"No structural model of HNRNPH2 qRRM–RNA or qRRM–LASR interface exists\",\n        \"The contribution of cytoplasmic HNRNPH2 gain-of-function versus nuclear loss-of-function to disease is not resolved\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [2, 7, 8]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [2, 6, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 4, 5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [2, 6, 8]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 4, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 4, 7]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [2, 4, 5]}\n    ],\n    \"complexes\": [\n      \"LASR splicing complex\"\n    ],\n    \"partners\": [\n      \"TNPO1\",\n      \"HNRNPH1\",\n      \"HNRNPF\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}